1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Zymeworks Inc (ZYME)
  7. Quote


Zymeworks Stock Price

0.73 (3.17%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.73 3.17% 23.73 18:00:02
Open Price Low Price High Price Close Price Prev Close
23.03 23.03 23.90 23.73 23.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,692 301,825 $ 23.50 $ 7,091,725 - 22.42 - 59.03
Last Trade Time Type Quantity Stock Price Currency
19:00:00 13,422 $ 23.73 USD


Draw Mode:

Zymeworks Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.10B 46.55M 37.67M $ 38.95M $ - -3.57 -5.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -10.44k 1.00%

more financials information »

Zymeworks News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZYME Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.0026.04522.4223.24855,707-2.27-8.73%
1 Month28.3630.179922.4225.80709,288-4.63-16.33%
3 Months32.0737.1922.4229.72532,679-8.34-26.01%
6 Months28.3039.4122.4231.66485,687-4.57-16.15%
1 Year40.7459.0322.4236.22473,676-17.01-41.75%
3 Years12.7159.0310.7234.28368,68611.0286.7%
5 Years13.5059.036.2532.68268,01210.2375.78%

Zymeworks Description

Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.